|Company:||CV Therapeutics, Inc.|
|Ticker Symbol:||NASD: CVTX|
|Class Period:||May 14, 2003 through Aug. 1, 2003|
|Court:||Northern District, CA|
|Lead Plaintiff Deadline:||Oct-10-03|
CV Therapeutics is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of cardiovascular diseases. The Complaint alleges that defendants violated federal securities laws by issuing a series of material misrepresentations to the market during the Class Period about CV Therapeutics' New Drug Application for Ranexa, a drug for the treatment of chronic angina, thereby artificially inflating the price of CV Therapeutics securities.
If you acquired the securities of CV Therapeutics, Inc. during the Class Period you may, no later than October 10, 2003, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
If you feel you qualify for damages or remedies that might be awarded in this class action please fill in our form on the right to submit your complaint.
If your injustice does not match the complaint described above, please use this form to register your complaint. Thank you.